Brokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) Price Target at $106.25

Vaxcyte, Inc. (NASDAQ:PCVX) has earned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $106.25.

PCVX has been the subject of several recent analyst reports. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, September 12th. They issued a “neutral” rating and a $38.00 target price for the company.

Institutional Investors Weigh In On Vaxcyte

Large investors have recently bought and sold shares of the company. AlphaQuest LLC bought a new stake in Vaxcyte in the first quarter valued at approximately $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Vaxcyte in the first quarter valued at approximately $35,000. IFP Advisors Inc increased its position in shares of Vaxcyte by 376.4% during the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock worth $62,000 after acquiring an additional 1,306 shares in the last quarter. CWM LLC increased its position in shares of Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after acquiring an additional 1,115 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its position in shares of Vaxcyte by 81.6% during the first quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock worth $73,000 after acquiring an additional 867 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $41.35 on Friday. The company’s 50 day simple moving average is $37.46 and its 200 day simple moving average is $34.83. Vaxcyte has a fifty-two week low of $27.66 and a fifty-two week high of $116.00. The firm has a market capitalization of $5.37 billion, a P/E ratio of -10.06 and a beta of 1.07.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same quarter last year, the business posted ($0.83) EPS. Sell-side analysts expect that Vaxcyte will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.